Effect of an Effervescent Multivitamin on Color and Surface Roughness of Micro-Hybrid Dental Resin Composites.

The use of multivitamins has become widespread globally, yet there is a scarcity of studies investigating their impact on resin composite restorations. This study aimed to evaluate the effect of an effervescent multivitamin tablet on micro-hybrid dental resin composites' surface roughness and color. Fifty disc-shaped samples (8 × 2 mm, shade A2; n = 10) were prepared and polished using five different micro-hybrid resin composites (Pergamon, Dentac, Turkey; Estelite Posterior, Tokuyama, Japan; Geanial Anterior, GC, Japan; Charisma Opal, Kulzer, Germany; Beautifil II, Shofu, USA). Samples were immersed in 200 mL water to one effervescent multivitamin tablet (Redoxon Triple Action, Bayer) at 24 °C for 2 min a day in 24 h intervals for 30 days. All samples' surface roughness (Ra) and ΔE(L*a*b) measurements were recorded at the beginning and end of the 30 days. The Wald chi-square and a two-way ANOVA were used for statistical analysis (significance level p < 0.05). The resin composite type and exposure to the multivitamin had a statistically significant effect on Ra values (p < 0.05). The resin composite type had a statistically significant effect on ΔE values, likely due to the higher mean value of BII (p = 0.040). The surface roughness and color of resin composites can be affected by multivitamins with a pH value of 3.0. Therefore, it is important to consider the patient's routine vitamin intake during resin composite selection. Additional research is required to explore the properties of different dental restorative materials.

Results of Influenza Vaccination: Short Follow-Up Study of a Turkish Population.

INTRODUCTION: The trivalent inactivated influenza vaccine was approved for use in Turkey during the 2018-2019 influenza season. We evaluated beliefs regarding the vaccine and vaccination outcomes in a Turkish population. METHODS: Individuals who were vaccinated with the trivalent inactivated influenza vaccine between November 1 and December 31, 2018, at the Sisli Hamidiye Training and Research Hospital in Istanbul, Turkey, were included in this study. A 15-item questionnaire was completed by a physician during a face-to-face interview with the participants. All participants were followed during the 2018-2019 influenza season through May 2019. The participants were instructed to consult the same physician in case of sudden illness. Participants' beliefs and outcomes were assessed by their vaccination status for the 2017-2018 influenza season. RESULTS: A total of 150 participants were recruited. Their median age was 66 (range, 22-88) years. During the 2017-2018 influenza season, 4.1% had been hospitalized, 53.5% had developed an upper respiratory disease (URD), and 16.2% had been diagnosed with pneumonia. There were no cases of influenza, pneumonia, or hospitalization in the 2019 season; 49.3% of the participants developed a URD (n = 74). Among participants who had been vaccinated during both influenza seasons, 47.5% had had and/or developed a URD, with a higher number of cases during the 2018-2019 season. CONCLUSIONS: After vaccination, no cases of influenza, hospitalization, and pneumonia were observed and the incidence of URD decreased compared with that of the previous season.

Results of Influenza Vaccination: Short Follow-Up Study of a Turkish Population

Abstract INTRODUCTION: The trivalent inactivated influenza vaccine was approved for use in Turkey during the 2018-2019 influenza season. We evaluated beliefs regarding the vaccine and vaccination outcomes in a Turkish population. METHODS: Individuals who were vaccinated with the trivalent inactivated influenza vaccine between November 1 and December 31, 2018, at the Sisli Hamidiye Training and Research Hospital in Istanbul, Turkey, were included in this study. A 15-item questionnaire was completed by a physician during a face-to-face interview with the participants. All participants were followed during the 2018-2019 influenza season through May 2019. The participants were instructed to consult the same physician in case of sudden illness. Participants' beliefs and outcomes were assessed by their vaccination status for the 2017-2018 influenza season. RESULTS: A total of 150 participants were recruited. Their median age was 66 (range, 22-88) years. During the 2017-2018 influenza season, 4.1% had been hospitalized, 53.5% had developed an upper respiratory disease (URD), and 16.2% had been diagnosed with pneumonia. There were no cases of influenza, pneumonia, or hospitalization in the 2019 season; 49.3% of the participants developed a URD (n = 74). Among participants who had been vaccinated during both influenza seasons, 47.5% had had and/or developed a URD, with a higher number of cases during the 2018-2019 season. CONCLUSIONS: After vaccination, no cases of influenza, hospitalization, and pneumonia were observed and the incidence of URD decreased compared with that of the previous season.